EGFR and atherosclerosis: Furthermore, we found that nine key pathways are likely to be involved: pathways in cancer, proteoglycans in cancer, MicroRNAs in cancer, central carbon metabolism in cancer, lipid and atherosclerosis, Kaposi sarcoma-associated herpesvirus infection, ErbB signaling pathway, and EGFR tyrosine kinase inhibitor resistance, by which nitazoxanide treats HCC.